Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data”

por Garcia‐Cremades, Maria, Solans, Belen P., Hughes, Emma, Ernest, Jacqueline P., Wallender, Erika, Savic, Radojka M.
Publicado 2020

Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing

por Garcia‐Cremades, Maria, Solans, Belen P., Hughes, Emma, Ernest, Jacqueline P., Wallender, Erika, Aweeka, Francesca, Luetkemeyer, Anne F., Savic, Radojka M.
Publicado 2020

Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs

por Ernest, Jacqueline P., Goh, Janice Jia Ni, Strydom, Natasha, Wang, Qianwen, van Wijk, Rob C., Zhang, Nan, Deitchman, Amelia, Nuermberger, Eric, Savic, Rada M.
Publicado 2023

Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders

por Yi, Bitna, Jahangir, Alam, Evans, Andrew K., Briggs, Denise, Ravina, Kristine, Ernest, Jacqueline, Farimani, Amir B., Sun, Wenchao, Rajadas, Jayakumar, Green, Michael, Feinberg, Evan N., Pande, Vijay S., Shamloo, Mehrdad
Publicado 2017

Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis

por Ernest, Jacqueline P., Sarathy, Jansy, Wang, Ning, Kaya, Firat, Zimmerman, Matthew D., Strydom, Natasha, Wang, Han, Xie, Min, Gengenbacher, Martin, Via, Laura E., Barry, Clifton E., Carter, Claire L., Savic, Radojka M., Dartois, Véronique
Publicado 2021